九安医疗
(002432)
| 流通市值：176.70亿 | | | 总市值：187.41亿 |
| 流通股本：4.38亿 | | | 总股本：4.65亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,069,311,569.11 | 765,265,184.21 | 506,998,641.12 | 2,592,196,225.39 |
| 营业收入 | 1,069,311,569.11 | 765,265,184.21 | 506,998,641.12 | 2,592,196,225.39 |
| 二、营业总成本 | 1,275,596,464.12 | 897,862,987.49 | 442,333,724.73 | 1,884,214,150.2 |
| 营业成本 | 369,995,524.32 | 258,813,949.77 | 149,770,807.82 | 760,198,389.82 |
| 税金及附加 | 1,968,240.06 | 1,505,858.83 | 779,204.23 | 6,582,480.78 |
| 销售费用 | 286,935,389.67 | 199,231,881.02 | 119,621,932.97 | 457,583,724.5 |
| 管理费用 | 400,638,725.18 | 293,967,905.08 | 114,843,204.97 | 405,793,990 |
| 研发费用 | 223,974,991.76 | 166,396,386.62 | 88,219,341.37 | 260,687,058.95 |
| 财务费用 | -7,916,406.87 | -22,052,993.83 | -30,900,766.63 | -6,631,493.85 |
| 其中:利息费用 | 87,661,109.27 | 54,527,455.57 | 18,973,353.68 | 67,161,102.4 |
| 其中:利息收入 | 109,731,439.07 | 75,555,419.19 | 33,343,260.51 | 87,977,360.59 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,251,365,123.94 | 733,616,951.84 | 56,094,362.99 | 739,621,509.38 |
| 加:投资收益 | 562,473,424.73 | 391,267,595.65 | 185,950,284.32 | 712,470,809.9 |
| 资产处置收益 | 1,044,484.58 | 949,866.31 | 47,243.33 | 670,163.79 |
| 资产减值损失(新) | -13,872,019.25 | -10,599,732.01 | -534,167.38 | -53,479,088.87 |
| 信用减值损失(新) | -2,330,146.47 | -3,598,921.77 | -3,919,914.6 | -2,629,134.69 |
| 其他收益 | 2,672,898.64 | 2,053,171.11 | 1,252,880.97 | 5,165,782.91 |
| 四、营业利润 | 1,595,068,871.16 | 981,091,127.85 | 303,555,606.02 | 2,109,802,117.61 |
| 加:营业外收入 | 1,874,420.48 | 462,806.95 | 246,505.8 | 1,828,061.58 |
| 减:营业外支出 | 636,145.43 | 509,942.05 | 300,643.61 | 4,760,361.13 |
| 五、利润总额 | 1,596,307,146.21 | 981,043,992.75 | 303,501,468.21 | 2,106,869,818.06 |
| 减:所得税费用 | 8,548,712.55 | 60,868,696.92 | 25,685,810.71 | 306,827,673.26 |
| 六、净利润 | 1,587,758,433.66 | 920,175,295.83 | 277,815,657.5 | 1,800,042,144.8 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,587,758,433.66 | 920,175,295.83 | 277,815,657.5 | 1,800,042,144.8 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,589,064,898.75 | 920,173,702.2 | 266,282,253.63 | 1,668,727,334.63 |
| 少数股东损益 | -1,306,465.09 | 1,593.63 | 11,533,403.87 | 131,314,810.17 |
| 扣除非经常损益后的净利润 | 1,577,970,459.76 | 880,819,463.65 | 230,284,295.85 | 1,680,531,981.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 3.66 | 2.1 | 0.6 | 3.81 |
| (二)稀释每股收益 | 3.64 | 2.1 | 0.6 | 3.78 |
| 八、其他综合收益 | 81,832,104.69 | 361,186,484.93 | 240,079,618.96 | 696,472,446.46 |
| 归属于母公司股东的其他综合收益 | 82,959,399.81 | 360,735,276.45 | 239,038,888.16 | 679,212,858.17 |
| 九、综合收益总额 | 1,669,590,538.35 | 1,281,361,780.76 | 517,895,276.46 | 2,496,514,591.26 |
| 归属于母公司股东的综合收益总额 | 1,672,024,298.56 | 1,280,908,978.65 | 505,321,141.79 | 2,347,940,192.8 |
| 归属于少数股东的综合收益总额 | -2,433,760.21 | 452,802.11 | 12,574,134.67 | 148,574,398.46 |
| 公告日期 | 2025-10-25 | 2025-08-27 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |